Kelleher Financial Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Kelleher Financial Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-193,924	Closed	-$2.01M	–	89
2016 Q4	$2.01M	Buy	193,924 +6,774	+4%	+$74.4K	1.12%	31
2016 Q3	$2.32M	Sell	187,150 -500	-0.3%	-$6.53K	1.31%	28
2016 Q2	$2.02M	Buy	187,650 +43,750	+30%	+$466K	1.22%	29
2016 Q1	$1.59M	Buy	143,900 +61,900	+75%	+$615K	0.88%	38
2015 Q4	$1M	Buy	82,000 +79,000	+2,633%	+$1.23M	0.68%	43
2015 Q3	$50K	Buy	3,000 +1,500	+100%	+$33K	0.03%	114
2015 Q2	$31K	Hold	1,500	–	–	0.02%	118
2015 Q1	$26K	Hold	1,500	–	–	0.01%	121
2014 Q4	$25K	Buy	+1,500	New	+$21.4K	0.01%	115

Other funds holding AVDL

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Kelleher Financial Advisors's AVDL Position: Q1 2017 in Review

Kelleher Financial Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2017, closing a stake of 193,924 shares — an estimated $2.01M sold.

Kelleher Financial Advisors first reported a position in AVDL in Q4 2014 and held it in 9 quarters. The position peaked at $2.32M in Q3 2016. 74 funds tracked by Wall St. Rank hold AVDL as of Q1 2017.

Kelleher Financial Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Kelleher Financial Advisors sold 193,924 Avadel Pharmaceuticals shares in Q1 2017, an estimated $2.01M.
Kelleher Financial Advisors first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 9 quarters.
Kelleher Financial Advisors's Avadel Pharmaceuticals position peaked at $2.32M in Q3 2016.
74 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2017.

Based on Kelleher Financial Advisors's 13F filing for Q1 2017, filed 12 May 2017.